{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:07:02Z","timestamp":1789614422297,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T00:00:00Z","timestamp":1191283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00280-007-0601-x","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T13:02:03Z","timestamp":1191243723000},"page":"355-361","source":"Crossref","is-referenced-by-count":26,"title":["Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis"],"prefix":"10.1007","volume":"62","author":[{"given":"Ronald J.","family":"Bernardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bomgaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Balis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore F.","family":"Lagattuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Aikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Whitcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Renbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,2]]},"reference":[{"key":"601_CR1","first-page":"7915","volume":"50","author":"SM Blaney","year":"1990","unstructured":"Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG (1990) Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res 50:7915\u20137919","journal-title":"Cancer Res"},{"key":"601_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02780522","volume":"17","author":"SM Blaney","year":"2000","unstructured":"Blaney SM, Poplack DG (2000) Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol 17:151\u2013162","journal-title":"Med Oncol"},{"key":"601_CR3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","volume":"17","author":"C Bokemeyer","year":"1999","unstructured":"Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512\u2013516","journal-title":"J Clin Oncol"},{"key":"601_CR4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"601_CR5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","volume":"14","author":"GW Camiener","year":"1965","unstructured":"Camiener GW, Smith CG (1965) Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol 14:1405\u20131416","journal-title":"Biochem Pharmacol"},{"key":"601_CR6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J et al (1994) A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC early clinical trials group. Ann Oncol 5:543\u2013547","journal-title":"Ann Oncol"},{"key":"601_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-5002(02)00504-4","volume":"40","author":"YM Chen","year":"2003","unstructured":"Chen YM, Chen MC, Tsai CM, Perng RP (2003) Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis\u2014a case report. Lung Cancer 40:99\u2013101","journal-title":"Lung Cancer"},{"key":"601_CR8","first-page":"1059","volume":"70","author":"RC Donehower","year":"1986","unstructured":"Donehower RC, Karp JE, Burke PJ (1986) Pharmacology and toxicity of high-dose cytarabine by 72\u00a0h continuous infusion. Cancer Treat Rep 70:1059\u20131065","journal-title":"Cancer Treat Rep"},{"key":"601_CR9","first-page":"2437","volume":"8","author":"MJ Egorin","year":"2002","unstructured":"Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM (2002) Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res 8:2437\u20132442","journal-title":"Clin Cancer Res"},{"key":"601_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","volume":"17","author":"LH Einhorn","year":"1999","unstructured":"Einhorn LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509\u2013511","journal-title":"J Clin Oncol"},{"key":"601_CR11","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Estimation of areas. In: Gibaldi M (ed) Pharmacokinetics. Marcel Dekker, New York"},{"key":"601_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.mou.0000240310.70582.ce","volume":"16","author":"K Hendricksen","year":"2006","unstructured":"Hendricksen K, Witjes JA (2006) Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 16:361\u2013366","journal-title":"Curr Opin Urol"},{"key":"601_CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminoncol.2006.04.016","volume":"33","author":"KA Jaeckle","year":"2006","unstructured":"Jaeckle KA (2006) Neoplastic meningitis from systemic malignancies: diagnosis, prognosis, and treatment. Semin Oncol 33:312\u2013323","journal-title":"Semin Oncol"},{"key":"601_CR14","first-page":"595","volume":"15","author":"JA Kelley","year":"1987","unstructured":"Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, Johns DG (1987) The disposition and metabolism of 2\u2032,3\u2032-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 15:595\u2013601","journal-title":"Drug Metab Dispos"},{"key":"601_CR15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002800000253","volume":"47","author":"JZ Kerr","year":"2001","unstructured":"Kerr JZ, Berg SL, Dauser R, Nuchtern J, Egorin MJ, McGuffey L, Aleksic A, Blaney S (2001) Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 47:411\u2013414","journal-title":"Cancer Chemother Pharmacol"},{"key":"601_CR16","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1053\/j.seminoncol.2005.06.007","volume":"32","author":"HL Kindler","year":"2005","unstructured":"Kindler HL (2005) Front-line therapy of advanced pancreatic cancer. Semin Oncol 32:S33\u2013S36","journal-title":"Semin Oncol"},{"key":"601_CR17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.1552-4604.1988.tb03225.x","volume":"28","author":"RW Klecker Jr","year":"1988","unstructured":"Klecker RW Jr, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, Myers CE (1988) Pharmacokinetics of 2\u2032,3\u2032-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 28:837\u2013842","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"601_CR18","doi-asserted-by":"crossref","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","volume":"17","author":"D Lorusso","year":"2006","unstructured":"Lorusso D, Di Stefano A, Fanfani F, Scambia G (2006) Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17(5):v188\u2013v194","journal-title":"Ann Oncol"},{"key":"601_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cncr.20768","volume":"103","author":"BB Ma","year":"2005","unstructured":"Ma BB, Chan AT (2005) Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 103:22\u201331","journal-title":"Cancer"},{"key":"601_CR20","first-page":"520","volume":"40","author":"CL McCully","year":"1990","unstructured":"McCully CL, Balis FM, Bacher J, Phillips J, Poplack DG (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520\u2013525","journal-title":"Lab Anim Sci"},{"key":"601_CR21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00001622-200111000-00015","volume":"13","author":"C Nabhan","year":"2001","unstructured":"Nabhan C, Krett N, Gandhi V, Rosen S (2001) Gemcitabine in hematologic malignancies. Curr Opin Oncol 13:514\u201321","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"601_CR22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2006.06.013","volume":"60","author":"A Pace","year":"2006","unstructured":"Pace A, Fabi A (2006) Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 60(3):194\u2013200","journal-title":"Crit Rev Oncol Hematol"},{"key":"601_CR23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2006.07.004","volume":"32","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Pectasides M, Economopoulos T (2006) Systemic chemotherapy in locally advanced and\/or metastatic bladder cancer. Cancer Treat Rev 32:456\u2013470","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"601_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000055386","volume":"61","author":"JH Schiller","year":"2001","unstructured":"Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61(1):3\u201313","journal-title":"Oncology"},{"key":"601_CR25","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1053\/j.seminoncol.2006.03.020","volume":"33","author":"IE Smith","year":"2006","unstructured":"Smith IE (2006) Overview of gemcitabine activity in advanced breast cancer. Semin Oncol 33:S19\u2013S23","journal-title":"Semin Oncol"},{"key":"601_CR26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/07357900600815166","volume":"24","author":"S Stapleton","year":"2006","unstructured":"Stapleton S, Blaney S (2006) New agents for intrathecal administration. Cancer Invest 24:528\u2013534","journal-title":"Cancer Invest"},{"key":"601_CR27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T","volume":"85","author":"AM Storniolo","year":"1999","unstructured":"Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3,000 patients with pancreatic carcinoma. Cancer 85:1261\u20131268","journal-title":"Cancer"},{"key":"601_CR28","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1012208711013","volume":"12","author":"JF Vansteenkiste","year":"2001","unstructured":"Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine vs cisplatin-vindesine. Ann Oncol 12:1221\u20131230","journal-title":"Ann Oncol"},{"key":"601_CR29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","volume":"18","author":"AP Venook","year":"2000","unstructured":"Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 18:2780\u20132787","journal-title":"J Clin Oncol"},{"key":"601_CR30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/clpt.1984.120","volume":"35","author":"S Zimm","year":"1984","unstructured":"Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG (1984) Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 35:826\u2013830","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0601-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0601-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T22:16:05Z","timestamp":1629843365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0601-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0601-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,2]]}}}